EOLS News and Press, Evolus Inc. From 07/27/23

2023-07-27 11:42:19 ET Shares of Evolus (NASDAQ: EOLS) were up more than 25% as of 11 a.m. ET after the company reported record quarterly revenue and increased guidance. The stock is up 31% so far this year. Evolus is a customer-centric healthcare aesthetics company. Its lea...

2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...

Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter’s Growth Rate Achieved Record Growth and All-time Highs in New ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will be participating in Canaccord Genuity’s 43 rd Annual Growth Conference in Boston. Event: Canaccord ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2023 financial results and provide a business update on Wednesday, August 2, 2023, after the U.S. financial markets ...

2023-07-12 17:31:16 ET Gainers: Evolus ( NASDAQ: EOLS ) +5% . Omega Therapeutics ( OMGA ) +5% . Kodiak Sciences ( KOD ) +4% . Amazon ( AMZN ) +4% . Cara Therapeutics ( CARA ) +3% . Losers: ViaSat ( VSAT ) -7% ...

2023-06-29 14:51:32 ET Summary Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical data compared to established competitor Botox, agg...

Launching in the fourth largest aesthetic toxin injectables market in Europe 1 is part of the company’s geographic expansion strategy GP Dermal Solution will serve as distribution partner in Italy Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on ...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the completion of its Phase 2 clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau ® (prabotulinumtox...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced it recently completed the one-millionth Jeuveau ® redemption through its Evolus Rewards™ patient loyalty program. “We designed Evolus ...